Overview of Atorvastatin Tablets:

NOCLOGER Tablets contains Atorvastatin. By decreasing LDL-C and TG and increasing HDL-C, atorvastatin reduces the risk of cardiovascular morbidity and mortality. Atorvastatin has a unique structure, long half-life, and hepatic selectivity, explaining its greater LDL-lowering potency compared to other HMG-CoA reductase inhibitors.

box-nocloger


Atorvastatin is a HMG-CoA Reductase inhibitor.

NOCLOGER Tablets can be used in the treatment of following conditions:

  • Primary hypercholesterolemia and mixed dyslipidemia.
  • Primary dysbetalipoproteinemia who do not respond adequately to diet.
  • Elevated serum TG levels .
  • Homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable.
  • Reducing the risk of myocardial infarction, angina, stroke, revacularization procedures and hospitalization.


Hyperlipidemia (Heterozygous Familial And Nonfamilial) And Mixed Dyslipidemia (Fredrickson Types IIa and IIb): 10 or 20 mg NOCLOGER Tablet OD. Patients who require a large reduction in LDL-C (more than 45%) may be started at 40 mg OD. The dosage range is 10 to 80 mg OD.
Heterozygous Familial Hypercholesterolemia in Pediatric Patients (10-17 yrs of age): 10 mg NOCLOGER Tablet daily. The maximum recommended dose is 20 mg/day.
Homozygous Familial Hypercholesterolemia: 10mg to 80mg daily.
Concomitant Lipid-Lowering Therapy: It may be used with bile acid resins.

Atorvastatin selectively and competitively inhibits the hepatic enzyme HMG-CoA reductase. As HMG-CoA reductase is responsible for converting HMG-CoA to mevalonate in the cholesterol biosynthesis pathway, this results in a subsequent decrease in hepatic cholesterol levels. Decreased hepatic cholesterol levels stimulates upregulation of hepatic LDL-C receptors which increases hepatic uptake of LDL-C and reduces serum LDL-C concentrations.